Pro Medicus (ASX: PME) — Stock Profile

About Pro Medicus (ASX: PME)

Pro Medicus Limited is a healthcare informatics company focused on the development and supply of healthcare imaging software and radiology information system software and services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe. Its core offerings center on the Visage 7 Enterprise Imaging Platform, which gives radiologists, physicians, and clinicians access to and visualization of two-dimensional, three-dimensional, and four-dimensional medical images, alongside picture archive and communication system and digital imaging software.

The company also provides Visage RIS, a proprietary medical software covering practice management, training, installation, professional services, and after-sale support. Complementing these are Promedicus.net, an e-health platform supporting secure email and integration products, and two mobile applications, Visage Ease and Visage Ease Pro, which allow users to access medical imaging results and interpret diagnostic imaging studies stored on a Visage 7 server respectively. Incorporated in 1983, Pro Medicus is headquartered in Richmond, Australia.

MFAM Research

Our Exclusive Top 5 Stock Picks

Five high conviction stocks that didn't make the public list. Backed by institutional research with significant upside potential. Subscribe for free access.

Invalid email address
By subscribing, you consent to receive communications from us. You can unsubscribe at any time.

Latest Announcements

  • Pro Medicus (ASX: PME) – PME secures A$25M seven-year Valley Health contract
    August 21, 2026
    Pro Medicus Limited has secured a significant 7-year contract valued at A$25 million with Valley Health, a six-hospital healthcare system spanning Virginia and West Virginia. The deal marks a substantial win for the company’s cloud-based Visage 7 imaging platform in the North American market and demonstrates continued momentum in PME’s transformation toward a cloud-first strategy. […]
  • Pro Medicus (ASX: PME) – Pro Medicus Files FY26 Annual Report
    August 18, 2026
    Pro Medicus Limited has released its FY26 Annual Report, marking a key inflection point in how the medical imaging software company will communicate its performance and sustainability credentials to investors going forward. While the report itself spans the financial year ended 30 June 2026, its significance lies not in past performance details but in the […]
  • Pro Medicus (ASX: PME) – Pro Medicus Files FY26 Results Presentation
    August 18, 2026
    Pro Medicus delivered a strong financial performance in FY26, with revenue climbing 22.9% to A$261.7 million and underlying earnings before interest and tax rising 24.4% to A$196.1 million. In constant currency terms, growth accelerated, with revenue up 28.4% and EBIT up 30.6%, highlighting the underlying momentum in the business. This performance reinforces the company’s position […]
  • Pro Medicus (ASX: PME) – CEO Interview on FY26 Results
    August 18, 2026
    Pro Medicus Limited delivered full-year FY26 results that met management expectations, with net profit after tax increasing more than 32% on a constant currency basis. While reported results were affected by Australian dollar strength that impacted reported revenue by approximately $12 million and NPAT by $9.8 million, the underlying performance demonstrates sustained growth in the […]
  • Pro Medicus (ASX: PME) – Pro Medicus Reports Full Year Results
    August 18, 2026
    Pro Medicus delivered full-year underlying net profit of $144.7 million, up 24.1% year-on-year, exceeding the company’s own guidance for 30% growth when viewed on a constant currency basis at $154.5 million, up 32.5%. This result comes against a backdrop of strengthening order momentum, with the company securing $407 million in new contract wins during the […]
  • Pro Medicus (ASX: PME) – Pro Medicus Files FY26 Final Report
    August 18, 2026
    Pro Medicus Limited reported solid underlying operating performance in FY26, with revenue reaching A$261.7 million, up 22.9 percent from A$213.0 million in the prior year. More significantly, underlying profit before tax grew 24.2 percent to A$205.2 million from A$165.2 million, demonstrating that the company’s core business expansion is outpacing revenue growth through improved operational leverage. […]
  • Pro Medicus (ASX: PME) – Pro Medicus Secures Convertible Note from Echo IQ
    August 17, 2026
    I need the announcement text to write the commentary. You’ve provided the structure but the actual announcement content between the dashes is blank. I can see there’s supposed to be announcement text, but this session is non-interactive and can’t authenticate to the Office to pull attachments. Please paste the full announcement text directly into your […]
  • Pro Medicus (ASX: PME) – Pro Medicus Signs $23M St Luke’s Contract
    August 12, 2026
    Pro Medicus Limited has secured a A$23 million, seven-year contract with St. Luke’s Health System, a significant expansion of its footprint in the North American healthcare technology market. The agreement, announced on 12 August 2026, will deploy the company’s cloud-based Visage 7 enterprise imaging platform across one of Idaho’s largest health systems, which operates 10 […]
  • Pro Medicus (ASX: PME) – Pro Medicus Signs Echo IQ Finance Facility
    June 25, 2026
    Pro Medicus has entered into a binding Heads of Agreement with Echo IQ to establish both a financing arrangement and a reseller agreement for Echo IQ’s artificial intelligence solutions. The dual structure couples financial backing with commercial distribution rights, positioning PME to offer Echo IQ’s AI algorithms, including technologies for diagnosing aortic stenosis and heart […]
  • Pro Medicus (ASX: PME) – Pro Medicus Secures Binding Agreement with EIQ
    June 25, 2026
    Echo IQ Limited has secured a binding Heads of Agreement with Pro Medicus Limited, establishing a strategic investment and US commercial partnership worth up to A$20 million. Pro Medicus will invest an initial A$10 million, with an option to invest a further A$10 million contingent on FDA clearance of Echo IQ’s EchoSolv HF product. This […]
  • Pro Medicus (ASX: PME) – S&P DJI June 2026 Quarterly Rebalance
    June 5, 2026
    Pro Medicus Limited has been removed from the S&P/ASX 50 Index, effective from the open of trading on June 22, 2026, according to today’s announcement from S&P Dow Jones Indices regarding the quarterly rebalance. The removal comes as ALS Limited takes PME’s place in the index, marking a significant change in the composition of one […]
  • Pro Medicus (ASX: PME) – PME Renews A$16M OSU 2 Contract
    June 4, 2026
    Pro Medicus Limited has secured a five-year contract renewal worth A$16 million with The Ohio State University Wexner Medical Center, marking another significant milestone for the healthcare imaging software company. The renewal extends the company’s relationship with one of North America’s largest academic medical centers and demonstrates sustained customer demand for its Visage platform. What […]
  • Pro Medicus (ASX: PME) – Dr Sam Hupert CEO Interview
    June 1, 2026
    Pro Medicus has announced three significant healthcare contracts that executives believe signal resilience in a market spooked by artificial intelligence disruption. The largest is an A$90 million, seven-year agreement with Beth Israel Lahey Health in Boston, complemented by a US$23 million, five-year deal with University of Maryland Medical System announced in April, and the Tidal […]
  • Pro Medicus (ASX: PME) – PME renews five year Allegheny Health contract
    June 1, 2026
    Pro Medicus has secured a 5-year, A$28 million contract renewal with Allegheny Health Network, marking the third renewal with the large U.S. health system over a 10-year partnership. The deal expands PME’s platform footprint by adding Visage 7 Workflow to the existing installation, while incorporating improved commercial terms including higher transaction fees and increased minimum […]
  • Pro Medicus (ASX: PME) – PME wins A$16M TidalHealth 2 contract
    June 1, 2026
    Pro Medicus Limited has secured a seven-year contract valued at A$16 million with TidalHealth, a unified healthcare network comprising three hospitals serving the Mid-Atlantic region across Delaware, Maryland, and Virginia. The deal represents a significant revenue milestone for the Melbourne-based medical imaging software company and provides tangible evidence that its cloud-first strategy is gaining commercial […]
  • Pro Medicus (ASX: PME) – A$90M Seven-Year Deal with Lahey Health
    May 18, 2026
    Pro Medicus Limited has secured a A$90 million seven-year contract with Boston-based Beth Israel Lahey Health, marking a significant win for the Australian healthcare IT company’s cloud-based medical imaging platform. The contract spans the company’s full Visage 7 product suite, encompassing viewer, workflow and open archive components, and will be deployed across Beth Israel Lahey […]
  • Pro Medicus (ASX: PME) – Secures A$37M Northwestern Contract Extension
    April 13, 2026
    Pro Medicus Limited has secured a A$37 million contract renewal with Northwestern Medicine, one of the largest academic health systems in the United States. The five-year extension represents a significant validation of the company’s Visage 7 Viewer platform and underscores the strength of its client retention strategy in a competitive healthcare IT market. What makes […]

Financial Summary

Price History

Same Industry — HealthcareSame Sub-Industry — Health Information Services

No other covered stocks.

Share This